MARKET

VRDN

VRDN

Viridian Therapeutics Inc
NASDAQ
30.87
+0.39
+1.28%
After Hours: 30.87 0 0.00% 19:30 11/13 EST
OPEN
30.24
PREV CLOSE
30.48
HIGH
30.96
LOW
29.81
VOLUME
1.20M
TURNOVER
--
52 WEEK HIGH
34.29
52 WEEK LOW
13.18
MARKET CAP
3.51B
P/E (TTM)
-7.0628
1D
5D
1M
3M
1Y
5Y
1D
Is Viridian Therapeutics (VRDN) Undervalued Following Its Promising VRDN 008 Phase 1 Results?
Simply Wall St · 3d ago
How Phase 1 Success At Viridian Therapeutics (VRDN) Has Changed Its Investment Story
Simply Wall St · 4d ago
Viridian Therapeutics Price Target Raised to $44.00/Share From $42.00 by Wedbush
Dow Jones · 4d ago
Viridian Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 4d ago
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44
Benzinga · 4d ago
Viridian Therapeutics Is Maintained at Overweight by Wells Fargo
Dow Jones · 4d ago
Viridian Therapeutics Price Target Raised to $39.00/Share From $34.00 by Wells Fargo
Dow Jones · 4d ago
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39
Benzinga · 4d ago
More
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Webull offers Viridian Therapeutics Inc stock information, including NASDAQ: VRDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRDN stock methods without spending real money on the virtual paper trading platform.